We Would Be Buyers Of Sunshine Heart, Says Canaccord
In a research note published yesterday, Canaccord analyst Jason Mills reiterated a Buy rating on Sunshine Heart (NASDAQ:SSH) with a $10 price target.
Mills noted, “We would be buyers of SSH as our checks indicate accelerating enrollment in the US pivotal study, which we think is the most significant catalyst for the stock. We continue to believe SSH offers investors the opportunity to participate in a nascent growth company that is commercializing potentially disruptive technology for the treatment of moderate heart failure. We remain constructive on the long-term prospects for SSH’s differentiated technology in the treatment of Class III heart failure.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Mills has a total average return of -3.0% and a 46.0% success rate. Mills has a -34.4% average return when recommending SSH, and is ranked #3073 out of 3270 analysts.